Introduction
============

Gastric cancer is the fourth most common cancer and the second leading cause of cancer death worldwide [@B1]. Chromosomally unstable tumors account for 50% of gastric cancer based on The Cancer Genome Atlas network (TCGA) molecular classification [@B2]. Chromosomal instability refers to the rate that chromosomes or large portions of chromosomes are changed [@B3].

CHFR (checkpoint with forkhead associated and ring finger domains) gene locates at chromosome 12q24.33. It encodes an E3 ubiquitin ligase to promote the ubiquitination-dependent degradation of mitosis-related oncoproteins such as Kiff22 [@B4], PLK1 [@B5] and Aurora A [@B6]. By doing so, it functions as an early mitotic checkpoint that delays the entry from prophase into metaphase in response to mitotic stresses. Cancer cell lines with function loss of CHFR could bypass mitotic arrest induced by mitotic stresses [@B7]. CHFR expression is reduced in 20-50% of primary tumors and tumor cell lines [@B6].

Several studies suggested that CHFR gene expression is frequently silenced by promoter hypermethylation in gastric cancer [@B8]-[@B12]. Additionally, CHFR promoter methylation improved the gastric cancer sensitivity to microtubule inhibitors such as docetaxel and paclitaxel [@B13], [@B14]. However, the samples of these studies were too small to confirm solid results. Meta-analysis is a classical statistical method that can pool data from different studies and enhance the power to draw a more comprehensive conclusion than a single study [@B15]. Therefore, we performed a meta-analysis to explore the relevance of CHFR promoter methylation to gastric cancer. Moreover, public data from TCGA and Gene Expression Omnibus (GEO) database were also collected to further validate the influence of CHFR methylation on the prognosis of gastric cancer patients.

Methods
=======

Data collection
---------------

We collected studies from online index database PubMed, PubMed Centra (PMC), Embase, and Chinese database (WeiPu, WanFang and Chinese National Knowledge Infrastructure) without time and language limitation. The search keywords for PubMed were "((((((((((((checkpoint with forkhead and ring finger domains)) OR CHFR) OR RNF116) OR RNF196)) AND ((Gastric Cancers OR (Cancer of the Stomach) OR (Gastric Cancer) OR (Stomach Cancers) OR (Cancer of Stomach) OR (Gastric Neoplasm) OR (Gastric Neoplasms) OR (Stomach Neoplasm))))) AND methylation \[tiab\])) NOT (((animals \[mh\] NOT humans \[mh\]))))) NOT (\"review\" \[Publication Type\])". Similar search keywords were applied for other database. The search was updated before July, 2018. We would include studies met the follow items: (1) it is an original human clinical trial on association between CHFR promoter methylation and gastric cancer; (2) the study should involve sufficient data to calculate the odds ratios (OR) and 95%confidence index (95% CI) between CHFR methylation and gastric cancer, and if not, it should have data of CHFR methylation of relevant clinical characteristics; (3) the controls should be adjacent tissue from same patient, or benign lesion/normal gastric tissues from health population. Two reviewers have independently processed the study selection (DD and BZ), and disagreements of decisions were solved by discussion and subsequent consensus. If the same population was used in different studies, the most recent, largest, or best-quality one would be included.

Data extraction
---------------

The data extraction from articles included the name of first author, year of publication, the region where the samples were from, numbers of cases and controls, methods of detecting methylation status, sample types, tumor stages, control type and study type. The extraction was performed by two independent reviewers (DD and BZ).

Data analyses of meta-analysis
------------------------------

All the statistical analyses were performed by Stata software 11.0[@B16]. The OR and 95% CI were calculated. Cochran\'s Q statistic and I² test [@B17] were used to calculate statistical heterogeneity. Since random and fix model present similar results when heterogeneity is low, the random effect model was used in current meta-analyses [@B18]. Funnel plots were drawn to observe the potential publication bias. Begg and Egger analyses were also analyzed [@B19], [@B20]. A p value lower than 0.05 was considered significant.

Validation analysis by TCGA and GEO database
--------------------------------------------

We further collected data from public functional genomics data repository to validate the association between CHFR methylation and gastric cancer of current meta-analysis. A case-control designed and Infinium HumanMethylation27 BeadChip (HM27K) technical based study was selected from GEO database (GSE30601) [@B21], which involved 203 gastric tumors and 94 matched non-malignant gastric samples from Singapore. Moreover, prognostic analysis of CHFR was also performed in MethSurv [@B22], which contained TCGA stomach adenocarcinoma cohort that involved 395 patients whose cancer methylome status was tested by Infinium HumanMethylation450 BeadChip (HM450K). The follow-up time of this cohort was 449 days and 155 deaths were found after follow-up. The beta value of every CpG site was calculated as M/(M + U + 100), where M and U were methylated and unmethylated intensities, respectively. Different methylation status was defined by certain beta-value level (fully unmethylated, 0 \< beta-value \<= 0.2; partially methylated, 0.2 \< beta-value \< 0.6; fully methylated, 0.6 \<= beta-value \<= 1).

Results
=======

Data collection
---------------

As in Figure [1](#F1){ref-type="fig"}, we found 28 studies from PubMed, 58 studies from PMC, 28 studies from Embase and 40 studies from Chinese database. By reading titles and abstracts, and removing the duplicate studies, 48 full-text articles were selected for further screening. We next excluded 9 reviews, 5 cell line and animal based studies, 10 studies with duplicate population and 5 studies with no sufficient data for calculating. Finally, 19 studies [@B8]-[@B12], [@B14], [@B23]-[@B35] with 1,249 tumor tissues and 745 normal tissues were involved in our meta-analysis. Among them, there were 10 studies from Japan [@B11], [@B12], [@B25], [@B28]-[@B30], [@B32], [@B33], [@B36], [@B37], 7 studies from China [@B8]-[@B10], [@B14], [@B23], [@B24], [@B26] and 2 studies from Korea [@B27], [@B31]. There were 3 prospective studies [@B14], [@B23], [@B28] and 16 retrospective [@B8]-[@B12], [@B24]-[@B27], [@B29]-[@B33], [@B36], [@B37] studies.

The association between CHFR methylation and gastric cancer
-----------------------------------------------------------

We next explored the association between CHFR methylation and gastric cancer. The results showed that the CHFR methylation was significantly higher in gastric cancer than normal tissues (studies numbers = 15, cases/controls = 862/745, OR = 7.46, 95% CI = 4.99-11.14, I² = 32.20%, Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Since the involved studies were mainly performed in China, Japan and Korea, a further subgroup population based analysis was conducted. The results showed CHFR methylation was significantly higher in gastric cancers in all of the three regions (China: studies numbers = 5, cases/controls = 394/323, OR = 4.96, 95% CI = 3.16-7.80, I² = 14.00%; Japan: studies numbers = 8, cases/controls = 400/383, OR = 10.12, 95% CI = 5.30-19.34, I² = 38.40%; Korea: Studies numbers = 2, cases/controls = 68/39, OR = 15.91, 95% CI = 3.52-71.81, I² = 0.00%, Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Moreover, we analyzed the association between CHFR methylation and different clinical features of gastric cancer patients that comprised gender (males vs. females), age (\>= 60 vs. \< 60 years), tumor histology (intestinal type vs. diffused and mixed type), differentiation level (high vs. low/intermediate), tumor size (\>= 5cm vs. \< 5cm), degree of T stage (T3-4 vs. T1-2), tumor stage (III+IV vs. I+II), lymph node metastasis (positive vs. negative), distant metastasis (positive vs. negative) and P53 statue (mutation vs. wild). We found the CHFR methylation level was significant associated with the tumor size of gastric cancer (studies numbers = 6, cases/controls = 236/186, OR = 1.71, 95% CI = 1.11-2.65, I² = 16.00%, Table [2](#T2){ref-type="table"}). No significant results were found in other analyses (Table [2](#T2){ref-type="table"}).

Publications bias
-----------------

The funnel plot presented asymmetry shape of all involved studies, and the Egger test showed a significant result for funnel plot asymmetry, indicating potential publication bias in current meta-analysis. Therefore, a nonparametric trim was performed to assess the influence of these asymmetry studies. Six missing studies were filled in new pooled funnel plots, and the new plots presented symmetrical shape (Figure [3](#F3){ref-type="fig"}) meanwhile the CHFR methylation still significantly associated with gastric cancer (OR = 5.31, 95% CI = 3.45-8.14), suggesting that our results were solid.

Data analyses from GEO and TCGA database
----------------------------------------

As shown in Table [3](#T3){ref-type="table"}, after performing differential analyses between gastric cancers and matched gastric non-malignant samples from GSE30601, thirteen statistically significant probes were selected. Among them, seven strongly associated probes (cg00338702, cg04044684, cg17387870, cg19027571, cg20535781, cg23653008, cg27040423) (p \< 0.001) showed the CHFR methylation was higher in cancers than normal tissue. These 7 probes were from the same CpG island region (hg19, 131973620-131975130). The mean beta-value difference between groups was all over 0.1 in these 7 probes (Table [3](#T3){ref-type="table"}, Figure [S1](#SM0){ref-type="supplementary-material"}). On the other side, other probes presented limited mean beta-value difference (one was 0.1036 while the others were less than 0.034, Table [3](#T3){ref-type="table"}, Figure [S2](#SM0){ref-type="supplementary-material"}). Moreover, the mean beta-value was extremely high and presented as fully methylated status in both groups when used the other 6 probes (Table [3](#T3){ref-type="table"}, Figure [S2](#SM0){ref-type="supplementary-material"}), which might not reflect the promoter methylation status of CHFR. Hence, the overall methylation statue of the 7 sites in CpG island region 131973620-131975130 might present the association between CHFR promoter methylation and gastric cancer. Interestingly, prognostic analysis showed that CHFR promoter hypermethylation was associated with longer overall survival in gastric cancer patients. Eight probes were found to be significantly predicting a better prognosis of gastric cancer patients. Previous study found CHFR promoter methylation could predict the sensitivity of gastric cancers to microtubule inhibitors [@B33], which might explain why CHFR promoter hypermethylation played a protective role in gastric cancer.

Discussion
==========

CHFR is a key player in controlling chromosomal integrity. Compared with other mitotic checkpoint genes, CHFR is more frequently inactivated in cancers [@B7]. CHFR inactivation in cancers might be a result of promoter CpG island methylation meanwhile CHFR hypermethylation was found in a series of cancers [@B38]. Expression of CHFR mRNA was downregulated in 53% gastric cancers, and 16% of this 53% were found to be caused by DNA methylation [@B39]. Studies found that CHFR could play multiple roles in regulating growth rate, cellular invasion, motility, and genomic stability in cancer cells [@B40], [@B41]. The current study found CHFR promoter hypermethylation was associated with gastric cancer in eastern Asian countries that included China, Japan, and Korea. We also found CHFR promoter hypermethylation was associated with larger tumor size. To our knowledge, this is the most comprehensive meta-analysis of CHFR methylation and gastric cancer.

The association between CHFR inactivation and cancer prognosis were widely studied. The immunohistochemistry showed that diminished expression of CHFR protein was associated with poor prognosis of smoking-related squamous cell carcinoma of the lung [@B42]. Hypermethylation of CHFR was found to be a predictor for worse outcomes in lung cancer [@B43], colorectal cancer [@B44]. Interestingly, on the other side, CHFR inactivation caused by methylation could also predict the sensitivity to microtubule inhibitors (such as docetaxel and paclitaxel) in various cancers [@B29], [@B33], [@B45]-[@B48] including gastric cancer [@B29], [@B33]. CHFR inactivation that caused the fast entry from prophase into metaphase might be a reason for the sensitivity to microtubule inhibitors [@B38]. Docetaxel and paclitaxel are included in first and second line treatment of gastric cancer according to National Comprehensive Cancer Network (NCCN). Our results showed that CHFR methylation played a protective role in gastric cancer. A study [@B14] found that when treated with docetaxel, overall survival of gastric cancer patients was longer in the CHFR methylated group than in the CHFR unmethylated group, while in the groups treated with oxaliplatin, there was no significant difference in overall survival between the CHFR methylated group and the unmethylated group. We hypothesized that the protective role of CHFR methylation in gastric cancer might be a result of alternation of microtubule inhibitors sensitivity. The 8 methylation probes we found in current studies might be good markers for the prognosis of gastric cancer.

There are some limitations in current studies. First, the studies involved in current meta-analysis were mostly from eastern Asia, and the GEO data was also from Singapore, whose population are mostly Chinese, we expect to see more results from other regions. Second, the samples we collected were tissues, which were hard to obtain and might limit the clinical use. Studies from serum or gastric juice are needed for further study. Third, different methylation test methods were involved in current meta-analysis, which might cause systemic bias, however, no significant heterogeneity was found in current meta-analysis. Finally, more prognostic studies are needed for further analysis.

In conclusion, we found CHFR promoter hypermethylation was associated with gastric cancer and played a protective role in gastric cancer process.
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![Flowchart of selection process in the meta-analyses](jcav10p0949g001){#F1}

![Forest plots of CHFR methylation with gastric cancer. The large diamond at the bottle of the table represents the pooled odds ratio of all studies. The width of the diamond represents with 95% CI.](jcav10p0949g002){#F2}

![Funnel plots of CHFR methylation with gastric cancer. A, Funnel plots of association between CHFR promoter methylation and gastric cancer in tissues before nonparametric trim; B, Funnel plots of association between CHFR promoter methylation and gastric cancer in tissues after nonparametric trim or, odds ratio; SE, standard error; One cycle represents one individual study.](jcav10p0949g003){#F3}

###### 

Characteristics of the involved in current meta-analyses

  Author/Year      Regions   Cases/Controls   Methods         Samples   Tumor stages   Control type                                       Study type      Reference
  ---------------- --------- ---------------- --------------- --------- -------------- -------------------------------------------------- --------------- -----------
  Li Y/2015        China     102/0            MSP             Tissues   I-IV           NA                                                 Prospective     [@B14]
  Guo He/2014      China     70/0             MSP             Tissues   I-IV           NA                                                 Retrospective   [@B8]
  Wang M/2014      China     117/46           MethyLight      Tissues   NA             Adjacent tissue                                    Prospective     [@B23]
  Hiraki M/2011    Japan     127/20           q-MSP           Tissues   NA             Adjacent tissue                                    Retrospective   [@B36]
  Hu S/2010        China     70/70            MSP             Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B24]
  Hu S/2011        China     123/123          MSP             Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B9]
  Cheng Z/2010     China     64/64            MSP and COBRA   Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B10]
  Hiraki M/2010    Japan     49/49            q-MSP           Tissues   I-IV           Adjacent gastric mucosa and adjacent regional LN   Retrospective   [@B25]
  Oki E/2009       Japan     59/59            MSP             Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B11]
  Gao Y/2008       China     20/20            MSP             Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B26]
  Kang G/2008      Korea     25/25            MSP             Tissues   NA             chronic gastritis tissues from other patients      Retrospective   [@B27]
  Mitsuno M/2007   Japan     56/0             MSP             Tissues   I-IV           NA                                                 Prospective     [@B28]
  Morioka Y/2006   Japan     53/53            MSP             Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B12]
  Koga Y/2006      Japan     46/46            MSP             Tissues   NA             Adjacent tissue                                    Retrospective   [@B29]
  Yoshida K/2006   Japan     41/41            COBRA           Tissues   NA             Adjacent tissue                                    Retrospective   [@B37]
  Homma N/2004     Japan     52/0             MSP             Tissues   NA             Adjacent tissue                                    Retrospective   [@B30]
  Honda T/2004     Japan     71/71            MSP             Tissues   NA             Adjacent tissue                                    Retrospective   [@B32]
  Kang H/2004      Korea     43/14            COBRA           Tissues   I-IV           Adjacent tissue                                    Retrospective   [@B31]
  Satoh A/2003     Japan     61/44            COBRA           Tissues   NA             Adjacent tissue                                    Retrospective   [@B33]

MSP: methylation-specific polymerase chain reaction; COBRA: Combined Bisulfite Restriction Analysis; NA: not available.

###### 

Meta-analyses of CHFR methylation with gastric cancer

  Group                                                                             Studies number   Cases/Controls   OR (95% CI)           I² (%)   p value of I²   Begg    Egger
  --------------------------------------------------------------------------------- ---------------- ---------------- --------------------- -------- --------------- ------- ----------
  Studies with all races (Cancer tissues vs. Normal tissues)                        15               862/745          7.46 (4.99, 11.14)    32.20    0.111           0.023   \< 0.001
  China group (Cancer tissues vs. Normal tissues)                                   5                394/323          4.96 (3.16, 7.80)     14.00    0.325           0.462   0.099
  Japan group (Cancer tissues vs. Normal tissues)                                   8                400/383          10.12 (5.30, 19.34)   38.40    0.123           0.108   0.001
  Korea group (Cancer tissues vs. Normal tissues)                                   2                68/39            15.91 (3.52, 71.81)   0.00     0.633           NA      NA
  Gender (Males vs. Females)                                                        13               518/307          0.81 (0.58, 1.12)     0.00     0.565           0.200   0.257
  Age (\>=60 years vs. \<60 years)                                                  5                196/233          0.73 (0.49, 1.09)     0.00     0.512           0.462   0.492
  Tumor histology (Intestinal type vs. Diffused and mixed type)                     5                166/198          1.26 (0.79, 2.03)     9.20     0.354           0.462   0.554
  Differentiation (Well and moderately differentiated vs. Poorly differentiated )   6                233/214          0.99 (0.47, 2.11)     73.00    0.002           0.707   0.744
  Tumor size (\>=5cm vs. \<5cm)                                                     6                236/186          1.71 (1.11, 2.65)     16.00    0.311           0.260   0.141
  Tumor invasion (T3-4 vs. T1-2)                                                    8                315/158          0.84 (0.55, 1.27)     0.00     0.658           0.536   0.979
  Tumor stage (III/IV vs. I/II)                                                     11               492/235          1.03 (0.74, 1.43)     0.00     0.674           0.350   0.548
  Lymph node metastasis (N2/N3/N4 vs. N0/N1)                                        8                319/190          1.08 (0.73, 1.61)     0.00     0.601           0.902   0.617
  Distant metastasis (M1 vs. MO)                                                    4                44/236           1.32 (0.64, 2.73)     0.00     0.510           0.734   0.847
  P53 (Mutant vs. Wild)                                                             2                21/76            0.30 (0.07, 1.22)     28.70    0.236           1.000   NA

OR: odds ratio; 95% CI, 95%confidence index; NA: not available.

###### 

Significantly differential CHFR methylation probes from GEO database

  ID               adj.P.Val     Mean ± SEM of cancers   Mean ± SEM of normal tissues   Difference between means   RANGE_START     RANGE_END       GB_ACC
  ---------------- ------------- ----------------------- ------------------------------ -------------------------- --------------- --------------- ------------------
  **cg00338702**   **\<0.001**   **0.2998 ± 0.01393**    **0.1611 ± 0.008613**          **-0.1387 ± 0.02131**      **131973620**   **131975130**   **NM_018223.1**
  **cg04044684**   **\<0.001**   **0.3134 ± 0.01461**    **0.1214 ± 0.008635**          **-0.1919 ± 0.02228**      **131973620**   **131975130**   **NT_024477.13**
  **cg17387870**   **\<0.001**   **0.4747 ± 0.01233**    **0.3712 ± 0.009551**          **-0.1036 ± 0.01926**      **131973620**   **131975130**   **NM_018223.1**
  **cg19027571**   **\<0.001**   **0.2856 ± 0.01635**    **0.1291 ± 0.008534**          **-0.1565 ± 0.02474**      **131973620**   **131975130**   **NT_024477.13**
  **cg20535781**   **\<0.001**   **0.4656 ± 0.008622**   **0.3156 ± 0.007398**          **-0.1501 ± 0.01364**      **131973620**   **131975130**   **NT_024477.13**
  **cg23653008**   **\<0.001**   **0.1908 ± 0.01391**    **0.04342 ± 0.006138**         **-0.1474 ± 0.02088**      **131973620**   **131975130**   **NT_024477.13**
  **cg27040423**   **\<0.001**   **0.2112 ± 0.01223**    **0.09632 ± 0.005376**         **-0.1148 ± 0.01835**      **131973620**   **131975130**   **NM_018223.1**
  cg17003970       \<0.001       0.7878 ± 0.01172        0.8941 ± 0.002406              0.1063 ± 0.01731           131945626       131946355       NT_024477.13
  cg17524886       \<0.001       0.8925 ± 0.004785       0.9249 ± 0.002214              0.03244 ± 0.007198         131934293       131934917       NT_024477.13
  cg17904068       0.012         0.9083 ± 0.003359       0.8936 ± 0.003251              -0.01467 ± 0.005411        131930864       131931625       NT_024477.13
  cg20066677       0.037         0.8355 ± 0.004471       0.8513 ± 0.003603              0.01576 ± 0.007017         131934293       131934917       NT_024477.13
  cg21432513       0.005         0.8854 ± 0.007080       0.9169 ± 0.001714              0.03145 ± 0.01048          131945626       131946355       NT_024477.13
  cg22381955       \<0.001       0.9643 ± 0.002186       0.9766 ± 0.0008457             0.01227 ± 0.003267         131939857       131940762       NT_024477.13

SEM, standard error of the mean; RANGE_START POSITION. Chromosomal start position of oligo relative to chromosome accession version; RANGE_END Chromosomal end position of oligo relative to chromosome accession version; GB_ACC, GenBank accession; the probes from the CpG island region 131973620-131975130 were bolded.

###### 

CHFR played a protective roles in gastric cancer prognosis

  Name         HR (95% CI)            p value   CHR   MAPINFO    UCSC_RefGene_Group   Relation_to_UCSC_CpG_Island
  ------------ ---------------------- --------- ----- ---------- -------------------- -----------------------------
  cg00470794   0.631 (0.416, 0.959)   0.031     12    1.33E+08   TSS1500              Island
  cg02667335   0.660 (0.437, 0.997)   0.048     12    1.33E+08   TSS1500              Island
  cg04044684   0.644 (0.466, 0.891)   0.0079    12    1.33E+08   TSS1500              Island
  cg07951978   0.607 (0.397, 0.927)   0.021     12    1.33E+08   TSS1500              Island
  cg15063355   0.622 (0.407, 0.950)   0.028     12    1.33E+08   TSS1500              Island
  cg18533833   0.657 (0.433, 0.998)   0.049     12    1.33E+08   TSS1500              Island
  cg26832509   0.644 (0.424, 0.978)   0.039     12    1.33E+08   TSS1500              Island
  cg27382164   0.587 (0.384, 0.897)   0.014     12    1.33E+08   TSS1500              Island

HR, hazard ratio; 95% CI, 95%confidence index; CICHR, chromosome number of the site; MAPINFO, position of the site in the genome.
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